Selank
Last reviewed 2026-10-30
Our read Opinion
Small comparative anxiety studies exist. FDA places selank acetate among withdrawn nominations and highlights immunogenicity and inadequate human safety information.
- Type
- Approved outside US
- Regulatory status
- Reported Russian approval; not FDA-approved
- Compounding status
- Off Category 2, review pending
- FDA-approved indications
- None
- Evidence level
- Small/early human studies
- Routes studied
- —
- WADA
- Verify
- Developer
- —
Claims made by researchers, companies and users. Inclusion does not mean the claim is verified.
- —Claimed to reduce anxiety
- —Claimed to support focus and memory
A tuftsin-derived peptide investigated for anxiolytic effects, with proposed effects on enkephalin metabolism and inhibitory neurotransmission. The mechanism is not fully established in humans.
Used as an anxiolytic medicine in Russia; current Russian authorization details are unverified here. No FDA approval or EMA authorization was identified.
Statuses change; check the linked primary source.
Momentum Opinion
Watch
0 news items in last 30 days
The early anxiety findings warrant research, not equivalence claims with established treatments. Clinical marketing runs ahead of independent replication and long-term safety evidence.
No news yet for this peptide.
Sharper focus and memory with less anxiety: 'calm focus'.
Information only. Not medical advice. Listing a compound is not an endorsement or a recommendation to obtain or use it. Ratings and "Our Take" are editorial opinion. Full disclaimer.